Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

Journal of the American College of Cardiology

Volumn 31, Issue 3, 1998, Pages 684-691

  Williams, J Koudy ^a   Sukhova, Galina K ^b   Herrington, David M ^a   Libby, Peter ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DRUG EFFECT; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MACACA FASCICULARIS; PRAVASTATIN; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 18144435700     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00537-8     Document Type: Article

References (44)

1. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 78:1988;1157-1166.
2. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol. 66:1990;44G-47G.
3. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 12:1988;56-62.
4. Taeymans Y, Theroux P, Lesperance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation. 85:1992;78-85.
5. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
6. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
7. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 323:1990;946-955.
8. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
9. Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 15:1995;827-836.
10. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
11. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
12. Davies MJ, Thomas AC. Plaque fissuring the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina . Br Heart J. 53:1985;363-373.
13. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
14. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 71:1992;850-858.
15. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant morphology. Circulation. 89:1994;36-44.
16. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques the role of extracellular lipid, macrophages, and smooth muscle cell content . Br Heart J. 69:1993;377-381.
17. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes implications for plaque rupture . Circulation. 90:1994;775-778.
18. Willerson J, Hillis M, Winniford M, Buja L. Speculation regarding mechanisms responsible for acute ischemic heart disease syndrome. J Am Coll Cardiol. 8:1986;245-250.
19. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
20. Zeiher AM, Drexler H, Wollschlyger H, Just H. Modulation of coronary vasomotor tone in humans progressive endothelial dysfunction with different early stages of coronary atherosclerosis . Circulation. 83:1991;391-401.
21. Lopez JAG, Armstrong ML, Brotherton AF, Piegors DJ, Heistad DD. Effects of atherosclerosis and regression on vascular responses to products of activated platelets in primates. Am J Physiol. 260:1991;H1050-H1057.
22. Heistad DD, Mark AL, Marcus ML, Piegors DJ, Armstrong ML. Dietary treatment of atherosclerosis abolishes hyperresponsiveness to serotonin implications for vasospasm . Circ Res. 61:1987;346-351.
23. Heistad DD, Armstrong ML. Sick vessel syndrome can atherosclerotic arteries recover? Circulation. 89:1994;2447-2450.
24. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 80:1987;1808-1811.
25. Saxenhofer H, Weidmann P, Rieson WF, et al. Therapeutic efficacy of the HMG-CoA reductase inhibitor pravastatin in hyperlipoproteinemia type II. Eur J Clin Pharmacol. 39:1990;101-105.
26. Hunninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis. 85:1990;81-89.
27. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
28. Van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment of patients with angina pectoris. Circulation. 94:1996;1503-1506.
29. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
30. Kamata K, Kojima S, Sugiura M, Kasuya Y. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed mice by chronic administration of prazosin or pravastatin. Jpn J Pharmacol. 70:1996;149-156.
31. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
32. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation in vitro studies with inhibitors of HMG-CoA reductase . Atherosclerosis. 101:1993;117-125.
33. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total plasma cholesterol. Clin Chem. 20:1974;470-475.
34. Lipid Research Clinics Program. Manual of Laboratory Operations. Vol. 1: Lipid and Lipoprotein Analysis. Bethesda (MD): U.S. Department of Health Education and Welfare, publication no. (NIH) 75-628, 1974.
35. Parks JS, Pelkey SJ, Babiak J, Clarkson TB. Contraceptive steroid effects on lipids and lipoproteins in cynomolgus monkeys. Arteriosclerosis. 9:1989;261-268.
36. Williams JK, Vita JA, Manuck SB, Selwyn AP, Kaplan JR. Psychosocial factors impair vascular responses of coronary arteries. Circulation. 84:1991;2146-2153.
37. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 336:1990;129-133.
38. Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins and the progression of coronary atherosclerosis the Lieden Intervention Trial . N Engl J Med. 312:1985;805-811.
39. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 30:1972;675-680.
40. Applegate RJ, Herrington DM, Little WC. Coronary angiography more than meets the eye . Circulation. 87:1993;1399-1401.
41. Barger A, Beeuwkes IR, Lainey L, Silverman K. Hypothesis vasa vasorum and neovascularization of human coronary arteries . N Engl J Med. 310:1984;175-177.
42. Williams JK, Armstrong ML, Heistad DD. Vasa vasorum in atherosclerotic coronary arteries responses to vasoactive stimuli and regression of atherosclerosis . Circ Res. 62:1988;515-523.
43. Galis Z, Sukhova G, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA. 92:1995;402-406.
44. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.